Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T

The purpose of this work was to investigate whether noninvasive early detection (after the first cycle) of response to neoadjuvant chemotherapy (NAC) in breast cancer patients was possible. 31P‐MRSI at 7 T was used to determine different phosphor metabolites ratios and correlate this to pathological response.

[1]  Joseph V. Rispoli,et al.  Current and Emerging Magnetic Resonance-Based Techniques for Breast Cancer , 2020, Frontiers in Medicine.

[2]  Michael J van Rijssel,et al.  Correcting time‐intensity curves in dynamic contrast‐enhanced breast MRI for inhomogeneous excitation fields at 7T , 2019, Magnetic resonance in medicine.

[3]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Mike Clarke,et al.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials , 2018, The Lancet. Oncology.

[5]  Lucian A B Purvis,et al.  Using a whole-body 31P birdcage transmit coil and 16-element receive array for human cardiac metabolic imaging at 7T , 2017, PloS one.

[6]  Fernando Calamante,et al.  Gadolinium deposition in the brain: summary of evidence and recommendations , 2017, The Lancet Neurology.

[7]  F. Podo,et al.  Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer , 2016, Front. Oncol..

[8]  P. Luijten,et al.  Saturation‐transfer effects and longitudinal relaxation times of 31P metabolites in fibroglandular breast tissue at 7T , 2016, Magnetic resonance in medicine.

[9]  M. Papotti,et al.  Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up , 2016, Breast Cancer Research and Treatment.

[10]  P. Luijten,et al.  Whole‐body radiofrequency coil for 31P MRSI at 7 T , 2016, NMR in biomedicine.

[11]  Glycerophosphocholine and Glycerophosphoethanolamine Are Not the Main Sources of the In Vivo 31P MRS Phosphodiester Signals from Healthy Fibroglandular Breast Tissue at 7 T , 2016, Front. Oncol..

[12]  Wei Huang,et al.  Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI1 , 2016, Translational oncology.

[13]  Ahmedin Jemal,et al.  Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[14]  T. Bathen,et al.  In Vivo 31P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts , 2015, Journal of magnetic resonance imaging : JMRI.

[15]  M. A. van den Bosch,et al.  Detection of alterations in membrane metabolism during neoadjuvant chemotherapy in patients with breast cancer using phosphorus magnetic resonance spectroscopy at 7 Tesla , 2014, SpringerPlus.

[16]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[17]  S. Loibl,et al.  Surgical treatment of primary breast cancer in the neoadjuvant setting , 2014, The British journal of surgery.

[18]  P. Luijten,et al.  31P magnetic resonance spectroscopy of the breast and the influence of the menstrual cycle , 2014, Breast Cancer Research and Treatment.

[19]  W. J. M. Kemp,et al.  Adiabatic multi‐echo 31P spectroscopic imaging (AMESING) at 7 T for the measurement of transverse relaxation times and regaining of sensitivity in tissues with short T2* values , 2013, NMR in biomedicine.

[20]  Harish Poptani,et al.  MR spectroscopy of head and neck cancer. , 2013, European journal of radiology.

[21]  Ileana Hancu,et al.  On shimming approaches in 3T breast MRI , 2013, Magnetic resonance in medicine.

[22]  R. Balleine,et al.  Ki67 and proliferation in breast cancer , 2013, Journal of Clinical Pathology.

[23]  Increase in SNR for 31P MR spectroscopy by combining polarization transfer with a direct detection sequence , 2012, Magnetic resonance in medicine.

[24]  Peter R Luijten,et al.  Quantitative 31P magnetic resonance spectroscopy of the human breast at 7 T , 2012, Magnetic resonance in medicine.

[25]  P. Lønning,et al.  Predicting long‐term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling , 2012, NMR in biomedicine.

[26]  P. Lønning,et al.  Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy , 2012, BMC Cancer.

[27]  Cecilia Possanzini,et al.  31P MRSI and 1H MRS at 7 T: initial results in human breast cancer , 2011, NMR in biomedicine.

[28]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[29]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[30]  A. Børresen-Dale,et al.  Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models , 2010, BMC Cancer.

[31]  A. Padhani,et al.  Multiparametric imaging of tumor response to therapy. , 2010, Radiology.

[32]  T. Bathen,et al.  Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. , 2010, Journal of proteome research.

[33]  Fiona J Gilbert,et al.  Use of new imaging techniques to predict tumour response to therapy. , 2010, The Lancet. Oncology.

[34]  A. Shelton,et al.  Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study , 2010, BMC Cancer.

[35]  A. Hutcheon,et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.

[36]  P. Hohenberger,et al.  31Phosphorus‐magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors , 2002, Cancer.

[37]  F. Podo.  Tumour phospholipid metabolism , 1999, NMR in biomedicine.

[38]  R. Dixon.  NMR studies of phospholipid metabolism in hepatic lymphoma , 1998 .

[39]  T. Powles,et al.  Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment , 1998, NMR in biomedicine.

[40]  Y. Kitamoto,et al.  Early radiation effects in highly apoptotic murine lymphoma xenografts monitored by 31P magnetic resonance spectroscopy. , 1998, International journal of radiation oncology, biology, physics.

[41]  Vanhamme,et al.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge , 1997, Journal of magnetic resonance.

[42]  G. Pelosi,et al.  Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis , 1997, International journal of cancer.

[43]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[44]  R. Edwards,et al.  The assessment of treatment response in non-Hodgkin's lymphoma by image guided 31P magnetic resonance spectroscopy. , 1990, British Journal of Cancer.

[45]  M. Moerland,et al.  Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T. , 1988, Radiology.

[46]  C. Tanaka,et al.  Measurements of in vivo 31P nuclear magnetic resonance spectra in neuroectodermal tumors for the evaluation of the effects of chemotherapy. , 1985, Cancer research.